Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease
Thomas J. Kunicki
1
Division of Experimental Hemostasis and Thrombosis, of the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
,
Shirley A. Williams
2
Division of Hematology, The Children’s Hospital of Orange County, Orange, California, USA
,
Diane J. Nugent
2
Division of Hematology, The Children’s Hospital of Orange County, Orange, California, USA
,
Paul Harrison
3
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
,
Helen C. Segal
3
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
,
Anila Syed
4
Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
,
Peter M. Rothwell
5
University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK
› Author AffiliationsFinancial support: This study was supported by R01 Grant HL075821 from the NHLBI awarded to TJK and funding provided to DJN from The CHOC Foundation.
We studied the effect of prophylactic aspirin (ASA) ingestion on platelet function in 463 patients with stroke, transient ischemic attack (TIA) or acute coronary disease (ACD), using the Platelet Function Analyzer-100 (PFA-100). We correlated ASA responsiveness with haplotypes of seven candidate genes, selected for their documented role in platelet function, namely, the genes for integrins α2β1and αIIbβ3 (ITGA2, ITGA2B, and ITGB3), platelet glycoproteins Ibα and VI (GPIBA and GP6), the purinergic receptor P2Y1 (P2RY1), and prostaglandin H synthase 1 (PTGS1 = COX1). Non-responsiveness to ASA was defined as the failure of prior ASA ingestion to prolong the PFA-100 closure time (CT) when blood was perfused through cartridges coated with collagen plus epinephrine (CEPI-CT). ASA non-responsiveness was observed in 114 of 463 patients (24.6 %), but was not associated with haplotypes of any of the seven candidate genes. There was also no association between any haplotypes and the CT when blood was perfused through cartridges coated with collagen plus ADP (CADP-CT). The ASA non-responsive cohort had significantly increased whole blood platelet counts (p = 0.03) and plasma von Willebrand Factor antigen levels (p<0.001), which likely contributes to resistance to the inhibitory effects of ASA in the PFA-100.
Keywords
Aspirin -
PFA-100 -
platelet -
SNP -
VWF
References
1 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2
Gum PA,
Kottke-Marchant K,
Poggio ED.
et al.
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
4
Eikelboom JW,
Hankey GJ.
Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs 2004; 04: 57-67.
5
Gum PA,
Kottke-Marchant K,
Welsh PA.
et al.
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
8
Gasparyan AY,
Watson T,
Lip GY.
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
10
Harrison P,
Segal H,
Silver L.
et al.
Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119-124.
11
Homoncik M,
Jilma B,
Hergovich N.
et al.
Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316-321.
12
Rothwell PM,
Coull AJ,
Giles MF.
et al.
Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933.
13
Rothwell PM,
Coull AJ,
Silver LE.
et al.
Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773-1783.
15
Harrison P,
Segal H,
Blasbery K.
et al.
Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-1005.
16
Harrison P,
Robinson MS,
Mackie IJ.
et al.
Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 25-31.
18
Crescente M,
Di CA,
Lacoviello L.
et al.
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
19
Jacquelin B,
Tarantino MD,
Kritzik M.
et al.
Allele-dependent transcriptional regulation of the human integrin alpha 2 gene. Blood 2001; 97: 1721-1726.
20
Kritzik M,
Savage B,
Nugent DJ.
et al.
Nucleotide polymorphisms in the alpha 2 gene define multiple alleles which are associated with differences in platelet alpha 2 beta 1. Blood 1998; 92: 2382-2388.
21
Kalb R,
Santoso S,
Unkelbach K.
et al.
Localization of the Br polymorphism on a 144 bp Exon of the GPIa gene and its application in platelet DNA typing. Thromb Haemost 1994; 71: 651-654.
22
Di Paola J,
Jugessur A,
Goldman T.
et al.
Platelet glycoprotein Ibalpha and integrin alphabeta polymorphisms: gene frequencies and linkage disequilibrium in a population diversity panel. J Thromb Haemost 2005; 03: 1511-1521.
23
Reiner AP,
Kumar PN,
Schwartz SM.
et al.
Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31: 1628-1633.
24
Newman PJ,
Derbes RS,
Aster RH.
The human platelet alloantigens, PLA1 and PLA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781.
25
Afshar-Kharghan V,
Li CQ,
Khoshnevis-Asl M.
et al.
Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib- IX-V complex. Blood 1999; 94: 186-191.
27
Kuijpers RWAM,
Faber NM,
Cuypers HTM.
et al.
NH2-Terminal globular domain of human platelet glycoprotein Iba has a methionine145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. J Clin Invest 1992; 89: 381-384.
28
Murata M,
Furihata K,
Ishida F.
et al.
Genetic and structural characterization of an amino acid dimorphism in glycoprotein Iba involved in platelet transfusion refractoriness. Blood 1992; 79: 3086-3090.
29
Kunicki TJ,
Federici AB,
Salomon DR.
et al.
An association of candidate gene haplotypes and bleeding severity in Von Willebrand Disease (VWD) type 1 pedigrees. Blood 2004; 104: 2359-2367.
30
Joutsi-Korhonen L,
Smethurst PA,
Rankin A.
et al.
The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 2003; 101: 4372-4379.
33
Chakroun T,
Gerotziafas G,
Robert F.
et al.
In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-85.
34
Reny JL,
de MP,
Dauzat M.
et al.
Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 06: 444-450.
36
Snoep JD,
Hovens MM,
Eikenboom JC.
et al.
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
37
Crescente M,
Di CA,
Lacoviello L.
et al.
PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99: 1129-1131.
38
Ye Z,
Liu EH,
Higgins JP.
et al.
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
41
Michelson AD,
Furman MI,
Goldschmidt-Clermont P.
et al.
Platelet GP IIIa PI(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-1018.
42
Szczeklik A,
Undas A,
Sanak M.
et al.
Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 965-967.
43
Szczeklik A,
Sanak M,
Undas A.
Platelet glycoprotein IIIa pl(a) polymorphism and effects of aspirin on thrombin generation. Circulation 2001; 103: E33-E34.
44
Macchi L,
Christiaens L,
Brabant S.
et al.
Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119.
45
Cooke GE,
Liu-Stratton Y,
Ferketich AK.
et al.
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47: 541-546.
47
Lev EI,
Patel RT,
Guthikonda S.
et al.
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-360.
48
Bernardo E,
Angiolillo DJ,
Ramirez C.
et al.
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17: 586-590.
49
Kunicki TJ,
Kritzik M,
Annis DS.
et al.
Hereditary variation in platelet integrin α2β1 copy number is associated with two silent polymorphisms in the a2 gene coding sequence. Blood 1997; 89: 1939-1943.
51
Lepantalo A,
Mikkelsson J,
Resendiz JC.
et al.
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
52
Takahashi S,
Ushida M,
Komine R.
et al.
Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121: 509-517.
53
Macchi L,
Christiaens L,
Brabant S.
et al.
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49.
